A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)

Trial Profile

A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Cetuximab (Primary) ; Antineoplastics
  • Indications Colorectal cancer; Head and neck cancer
  • Focus Adverse reactions; Registrational
  • Sponsors Merck KGaA
  • Most Recent Events

    • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
    • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
    • 01 Mar 2013 Planned end date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record (NCT01075828).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top